Volpara Health takes another milestone with 200 peer-reviewed articles

0
Copyright 2021 PR Newswire. All rights reserved
2021-10-11

LYNNWOOD, Wash., October 11, 2021 / PRNewswire / – Volpara Health is proud to have reached its 200e Peer-reviewed paper milestone, making the Volpara AI breast health platform the most independently validated of its kind. Volpara has also been featured in over 200 additional scientific works, including conference presentations, books and review articles. Achieving this achievement has taken a decade and emphasizes the company’s investment in using science and research to create evidence-based solutions that improve breast cancer detection, risk assessment and results. Since the creation of the company in 2009, based on a technology resulting from the Oxford UniversityVolpara focused on building relationships with researchers and supporting them in their quest to better understand breast cancer risk and prevention.

Volpara’s robust algorithm has firmly established the company as a trusted research partner through numerous high profile studies, which have already generated a number of publications. This research includes custom screening and optimization studies, such as DENSE1, TOMMY2, and future3 tests, and PROCAS I / II4 and KARMA5 studies. For example, the DENSE trial, led by the professor Carla van Gils of the University Medical Center Utrecht, The Netherlands, relied on Volpara’s TruDensityMT produced to identify women with extremely dense breasts in their randomized controlled trial undergoing supplemental MRI. The resulting reduction in interval cancers led the Dutch government to vote unanimously to add MRI scans for women with extremely dense breasts to the national screening program.

“Volpara is an excellent product that provides a range of breast density measurements. Having access to Volpara for clinical research has enabled us to advance the field of breast cancer risk prediction,” said Dr. Karla Kerlikowske of University of California, San Francisco.

Research has consistently shown a strong association between volumetric breast density and breast cancer risk, including a collaboration between Dr. Adam brentnall and teacher Jack Cuzick (both at Queen Mary University of London, United Kingdom, and developers of the Tyrer-Cuzick (TC) breast cancer risk prediction model, Volpara co-founding professor Martin Yaffé (Sunnybrook Research Institute, Toronto, Ontario, Canada), principal investigator Dr. Jennifer harvey (Rochester University, NY) and colleagues. Their work demonstrated improved risk stratification by adding volumetric breast density from Volpara to the widely used Tyrer-Cuzick (TC) breast cancer risk prediction model.

“Volpara’s key improvement in density reporting is an objective and reproducible density value that can be used in risk assessment models. These models are increasingly used to determine whether a woman is eligible for MRI screening, and also to decide whether the risk is high enough to warrant preventative treatment to reduce risk, ”said Professor Cuzick.

Volpara’s research collaborations span multiple disciplines, which is only possible thanks to the company’s diverse team of scientists who are able to provide their expertise and ensure that researchers receive personalized support to fully benefit part of the software Volpara.

“You can’t go wrong with Volpara. They have a dedicated team who understand your mammographic mammography density research needs and will always answer your questions. Notably, they are constantly improving the software and algorithm that drives Volpara.” , Associate Professor Adetunji Toriola of Washington University School of Medicine said.

In an effort to save more families from cancer through optimal screening pathways for patients, Volpara’s research which is particularly promising at this time includes:

  • Understand the impact of automated image quality measurements on screening results.
  • Refine TruDensity measurements and extend its use to other modalities, such as contrast enhanced digital mammography.
  • Improve our understanding of breast density change to improve breast cancer risk prediction and response to medications, such as hormone replacement therapy and risk reducing medications

“We continue to use Volpara’s quantitative density measurements in studies … examining changes in breast density as a possible indicator of changes in breast cancer risk, for example in evaluating potential breast cancer interventions. risk reduction. We are also using Volpara density as input to an algorithm we developed to predict breast cancer masking in tissue density mammograms. The goal is precision screening where women for whom there is a high risk of cancer masking can be referred to alternative or additional screening modalities, ”said Prof Yaffe.

This sentiment is shared by the head of clinical research at Volpara, Ariane Chan, PhD: “There is a growing body of scientific, peer-reviewed evidence demonstrating that Volpara’s breast health platform is transforming personalized screening and leading to real improvements in patient care.

Regardless of the size of the business, this scale and volume of articles independently validating their portfolio is significant and impressive. Volpara is committed to continuing to support and collaborate with researchers to drive innovation and clinical advancements in breast cancer screening, risk assessment and prevention.

About Volpara Santé
Volpara provides an advanced AI software platform that works with the expertise of a healthcare provider to enable a high-quality, optimized and personalized cancer screening experience. From the moment a patient enters a clinic until the moment she achieves key results, the Volpara breast health platform collects and analyzes information to better understand a patient’s breast cancer risk, while objectively assessing image quality and opportunities for improving workflow. These capabilities are extended to screening for lung cancer. The Volpara Breast Health platform is backed by numerous patents, trademarks, and regulatory registrations, including FDA clearance and CE mark, and is validated by a volume of peer-reviewed publications unparalleled in the health care industry. breast cancer screening.

The references:

1. Screening for dense tissue and early breast tumors
2. A comparison of TOMosynthesis with digital mammography in the UK NHS breast cancer screening program
3. Digital breast tomosynthesis test in Bergen
4. Predict cancer risk at screening I / II
5. KARolinska MAmmography Project for predicting breast cancer risk

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/volpara-health-reaches-new-milestone-with-200-peer-reviewed-papers-301397370.html

SOURCE Volpara Health



Source link

Leave A Reply

Your email address will not be published.